ERBB3 and squamous cell lung carcinoma: As ERBB3 inhibition with a blocking antibody under development (GSK2849330) has been effective in NRG fusion-positive squamous cell carcinoma of the lung [249], it might be beneficial in CRPCs driven by CAF-mediated activation of ERBB3 [248].